What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea?
作者信息
Park Min Kyung, Kim Yoon Jun
机构信息
Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.
出版信息
Clin Mol Hepatol. 2023 Apr;29(2):332-334. doi: 10.3350/cmh.2023.0080. Epub 2023 Mar 16.
Abstract
摘要
相似文献
1
What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea?为缩小韩国肝细胞癌指南与实际临床实践之间的差异，应采取哪些措施？
Clin Mol Hepatol. 2023 Apr;29(2):332-334. doi: 10.3350/cmh.2023.0080. Epub 2023 Mar 16.
2
Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspective.肝细胞癌的临床实践指南与实际临床实践：韩国视角。
Clin Mol Hepatol. 2023 Apr;29(2):197-205. doi: 10.3350/cmh.2022.0404. Epub 2023 Jan 5.
3
2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.2018 韩国肝癌协会-韩国国家癌症中心肝细胞癌管理实践指南。
Korean J Radiol. 2019 Jul;20(7):1042-1113. doi: 10.3348/kjr.2019.0140.
4
Toward user-friendly and evidence-based practice guidelines for hepatocellular carcinoma.迈向用户友好型和基于证据的肝细胞癌实践指南
Clin Mol Hepatol. 2023 Apr;29(2):335-338. doi: 10.3350/cmh.2023.0107. Epub 2023 Mar 20.
5
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma.2022 KLCA-NCC 韩国肝细胞癌管理实践指南。
Clin Mol Hepatol. 2022 Oct;28(4):583-705. doi: 10.3350/cmh.2022.0294. Epub 2022 Oct 1.
6
2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.2014年韩国肝脏研究学会-国立癌症中心肝细胞癌管理韩国实践指南
Gut Liver. 2015 May 23;9(3):267-317. doi: 10.5009/gnl14460.
7
Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: experience of the Bologna Liver Oncology Group.临床实践中遵循美国肝病研究学会肝细胞癌治疗指南：博洛尼亚肝脏肿瘤学组的经验
Dig Liver Dis. 2014 Jun;46(6):549-55. doi: 10.1016/j.dld.2014.02.012. Epub 2014 Mar 14.
8
2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.2022KLCA-NCC 韩国肝细胞癌管理实践指南。
Korean J Radiol. 2022 Dec;23(12):1126-1240. doi: 10.3348/kjr.2022.0822.
9
Integrated prognostic and histogenomic justification of stage-directed therapy for single large hepatocellular carcinoma: a Korean nationwide registry study.单发性大肝细胞癌分期导向治疗的综合预后与组织基因组学依据：一项韩国全国性登记研究
Gut. 2022 Jun;71(6):1234-1236. doi: 10.1136/gutjnl-2021-325844. Epub 2021 Sep 7.
10
2022 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for Transarterial Therapy of Hepatocellular Carcinoma: What's New?2022年韩国肝癌协会-韩国国立癌症中心肝细胞癌经动脉治疗实践指南：有哪些新内容？
Korean J Radiol. 2023 Jan;24(1):6-9. doi: 10.3348/kjr.2022.0510.
引用本文的文献
1
Limited Generalizability of Retrospective Single-Center Cohort Study in Comparison to Multicenter Cohort Study on Prognosis of Hepatocellular Carcinoma.与多中心队列研究相比，回顾性单中心队列研究在肝细胞癌预后方面的可推广性有限。
J Hepatocell Carcinoma. 2024 Jul 1;11:1235-1249. doi: 10.2147/JHC.S456093. eCollection 2024.
本文引用的文献
1
Systemic therapy in advanced hepatocellular carcinoma.晚期肝细胞癌的全身治疗
Clin Mol Hepatol. 2023 Apr;29(2):516-519. doi: 10.3350/cmh.2023.0051. Epub 2023 Feb 20.
2
Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region.联合检测 PIVKA-II 和 AFP 在亚太地区肝细胞癌监测和随访中的应用。
Clin Mol Hepatol. 2023 Apr;29(2):277-292. doi: 10.3350/cmh.2022.0212. Epub 2023 Jan 30.
3
Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspective.肝细胞癌的临床实践指南与实际临床实践：韩国视角。
Clin Mol Hepatol. 2023 Apr;29(2):197-205. doi: 10.3350/cmh.2022.0404. Epub 2023 Jan 5.
4
Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease.全国性肝细胞癌监测对慢性肝病患者预后的影响。
Clin Mol Hepatol. 2022 Oct;28(4):851-863. doi: 10.3350/cmh.2022.0037. Epub 2022 Jun 3.
5
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma.2022 KLCA-NCC 韩国肝细胞癌管理实践指南。
Clin Mol Hepatol. 2022 Oct;28(4):583-705. doi: 10.3350/cmh.2022.0294. Epub 2022 Oct 1.
6
Surveillance for hepatocellular carcinoma: It is time to move forward.肝细胞癌监测：是时候向前迈进了。
Clin Mol Hepatol. 2022 Oct;28(4):810-813. doi: 10.3350/cmh.2022.0257. Epub 2022 Sep 6.
7
Hepatocellular carcinoma statistics in South Korea.韩国肝细胞癌统计数据。
Clin Mol Hepatol. 2021 Jul;27(3):512-514. doi: 10.3350/cmh.2021.0171. Epub 2021 Jun 21.
8
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
9
Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging.使用磁共振成像对肝细胞癌进行无创诊断时LI-RADS 2018与KLCA-NCC 2018的比较
Clin Mol Hepatol. 2020 Jul;26(3):340-351. doi: 10.3350/cmh.2020.0004. Epub 2020 Jun 4.
10
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
Zotero 插件